


Metabolic Risk Panel

Uncover hidden risk and take action with the **Metabolic Risk Panel**

Patient risk continues to climb for a **growing number of cardiometabolic diseases**.¹ Yet many patients are unaware of their own risk, including millions who have prediabetes.² Patients who don't understand their risk are unlikely to take the actions needed to prevent disease progression.

With insulin resistance being the foundation to metabolic syndrome and prediabetes, the opportunity to improve care is enormous:



41.8% of US adults has **metabolic syndrome**³



97.6 million adults have **prediabetes**; more than 8 in 10 don't know they have it²



38 million adults have progressed to **type 2 diabetes**²

Early identification offers the greatest possibility of success with lifestyle modification

The **Metabolic Risk Panel** from the Quest Cardiometabolic Center of Excellence at Cleveland HeartLab can help healthcare professionals uncover hidden risk sooner.

The Metabolic Risk Panel includes:

- Apolipoprotein B (ApoB)
- Insulin Resistance Panel with Score
- HbA1c
- Lipid panel

Improve patient outcomes through early identification

When it comes to patient risk, traditional testing may not tell the whole story. The Metabolic Risk Panel provides a clear path for earlier risk identification, offering data for deeper insight into the metabolic state of your patients than any one test alone. For example:

- **Coupling HbA1c with the Insulin Resistance Panel.** The Insulin Resistance Panel can identify risk for future metabolic risk or diabetes at its earliest stages, potentially before permanent damage has occurred
- **Measuring ApoB with triglycerides** can help you assess changes in lipid metabolism that are associated with early stages of metabolic dysfunction
- LDL-C and non-HDL-C measurements can be used with ApoB to **identify lipid discordance**, a phenomenon associated with metabolic syndrome and insulin resistance; identifying those with discordantly high ApoB uncovers risk that might otherwise be overlooked when LDL-C levels appear optimal

Armed with this information, you can help your patients take action to **reverse the course of disease progression**, preventing costly and debilitating diabetic and cardiovascular disease events.

Metabolic Risk Panel results come with an easy-to-interpret enhanced report

Test Name	Result & Unit	Optimal	Non-Optimal	Reference Interval	Units	Historical
LIPID PANEL						
CHOLESTEROL, TOTAL	178	<200	N/A	>200	mg/dL	
HDL CHOLESTEROL	57	>=40	N/A	<40	mg/dL	
TRIGLYCERIDES	122	<100	100-159	>159	mg/dL	
LDL CHOLESTEROL	107	<100	100-129	>129	mg/dL	
CHOLESTR. RATIO	3.2	<=3.5	3.6-5.0	>=5.0	ratio	
NON-HDL CHOLESTEROL	124	<100	100-159	>159	mg/dL	
APOLIPOPROTEIN B						
APOLIPOPROTEIN B	121	<=80	80-119	>119	mg/dL	
METABOLIC MARKERS						
HEMOGLOBIN A1c	5.5	<=5.6	5.7-6.4	>=6.5	% of total Hgb	
INSULIN, INTACT, LCOMMS	7.2	<=10	N/A	>10	uIU/mL	
C-PEPTIDE, LCOMMS	2.04	>=0.16	N/A	>=1.6	ng/mL	
INSULIN RESISTANCE SCORE	4.1	<=3	3.0-4	>=4	ratio	

Test name

Patient preparation

Test code

CPT codes

Metabolic Risk Panel

Overnight fasting required

39447

80061, 83036, 82172, 83525, 84681

Panel components may be ordered separately: Cardio IQ® Apolipoprotein B (91726), Cardio IQ Hemoglobin A1c (91732), Cardio IQ Insulin Resistance Panel with Score (36509; includes Insulin, Intact LC/MS/MS [93103], C-peptide, and calculated IR score), Lipid Panel, Cardio IQ (91716; includes total cholesterol [334], triglycerides [896], HDL-C [608], calculated LDL-C, cholesterol/HDL ratio, non-HDL-C, and Cardio IQ interpretative report)



Contact your Quest Diagnostics sales representative to learn more about the Metabolic Risk Panel.

References

1. Singh, A, Bruemmer, D. Cardiometabolic Risk: Shifting the Paradigm Toward Comprehensive Assessment*. *JACC Adv.* 2024 Apr, 3 (4). <https://doi.org/10.1016/j.jacadv.2024.100867>
2. CDC. A Report Card: Diabetes in the United States Infographic. Last updated May 15, 2024. <https://www.cdc.gov/diabetes/communication-resources/diabetes-statistics.html>
3. Liang X, Or B, Tsoi MF, et al. Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011-18. *Postgraduate Medical Journal.* 2023;99(1175): qgad008. doi:<https://doi.org/10.1093/postmj/qgad008>

Test codes may vary by location. Please contact your local laboratory for more information.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

QuestDiagnostics.com

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. SB9406 12/2024

